Accurate discrimination among cues signifying reward, danger or safety initiates the proper emotional response in order to guide behavior. Appropriate conditioned inhibition of fear in the presence of a safety cue would allow an organism to engage in reward seeking behaviors. There is currently little known about the mechanisms of reward, fear and safety cue discrimination and how a safety cue can inhibit fear and release reward seeking from inhibition. Here we assess reward, fear and safety cue learning together using a behavioral paradigm that has identified neurons that discriminate among these cues in the basolateral amygdala (BLA) (Sangha, Chadick, & Janak, 2013) . Dopamine signaling in the BLA has been implicated in discriminatory reward learning, learned fear responses and fear extinction. We tested the hypothesis that D1 receptor activity will influence reward-fearsafety cue discrimination by using the D1 receptor agonist, SKF-3839, and antagonist, SCH-23390, either systemically or within the BLA during discrimination learning in male Long Evans rats. We show that both the agonist and antagonist interfered with fear suppression in the presence of the safety cue, when administered systemically or when infused directly into the BLA. This indicates that altering D1 receptor activity in the basolateral amygdala impairs fear suppression during a safety cue. Neither the agonist or antagonist had a consistent negative impact on discriminatory reward seeking when infused into the BLA. However, systemic administration of the D1 receptor agonist did reduce reward seeking behavior during a task that included fear and safety cues. We did not observe a negative impact on reward seeking during systemic administration of a D1 receptor agonist in a task that only included reward cue + sucrose and nonreward cue + no sucrose pairings. This indicates the impairments we saw with the systemically applied agonist in the safety-fear-reward cue discrimination task were more likely due to effects on fear and/or motivation rather than on cue discrimination. Together, our data indicate that altered dopamine D1 receptor activity in the BLA may be a potential mechanism that leads to the impairment in fear suppression to the safety signal seen with PTSD patients.
Introduction
Post-traumatic Stress Disorder (PTSD) affects approximately 8.7% of the general population within their lifetime (Kessler et al., 2005) , and these patients are impaired in learning to suppress their fear response in the presence of a safety cue (Jovanovic et al., 2009) , and to extinguish fear (Morriss, Christakou, & Van Reekum, 2015) . PTSD is also comorbid with substance abuse disorders such as the use of alcohol, opioid, cocaine (Ouimette, Read, Wade, & Tirone, 2010) , and smoking (Forbes et al., 2015) , indicating there is an additional reward dysregulation in PTSD comorbid with substance abuse disorders.
Accurate discrimination among cues signifying danger, safety or reward initiates the proper emotional response in order to guide behavior. Since potentially rewarding and dangerous stimuli often occur simultaneously leading to opposing behaviors, reward-and fear-related circuits must interact in order to mediate these antagonistic behaviors. The amygdala is critical for both fear and reward learning (Wassum & Izquierdo, 2015) . In order to investigate how the fear, safety and reward circuits integrate, we have been training Long Evans rats to discriminate among (a) a fear cue paired with footshock, (b) a safety cue in the presence of the fear cue resulting in no footshock, and (c) a reward cue paired with sucrose delivery. A selective increase in freezing to the fear cue and reward seeking to the reward cue indicate good fear and reward discrimination, respectively. This procedure also produces significant suppression of freezing to the fear cue if in the presence of a safety cue (Sangha, 2015; Sangha, Chadick, & Janak, 2013; Sangha, Greba, Robinson, Ballendine, & Howland, 2014; Sangha, Robinson, Greba, Davies, & Howland, 2014) . Using this task, we have previously https://doi.org/10.1016/j.nlm.2017.11.011 Received 10 March 2017; Received in revised form 9 November 2017; Accepted 19 November 2017 identified neurons in the basolateral amygdala (BLA) that discriminate among these cues (Sangha et al., 2013) and have shown differential roles for the infralimbic and prelimbic regions of the prefrontal cortex in this task . Dopaminergic signaling within the BLA is important for both fear and reward learning. Within the BLA, dopamine levels increase during learned fear responses (de Oliveira et al., 2011) and D1 receptors are required for fear extinction (Hikind & Maroun, 2008) . Dopamine signaling is also implicated in discriminatory reward learning (Eagle, Olumolade, & Otani, 2014) . Both D1 and D2 receptor activity modulate risk decisions during a reward uncertainty task (Larkin, Jenni, & Floresco, 2016) . Dopamine D1 and D2 receptors are differentially expressed throughout the amygdala: D2 receptors are more selectively expressed in the central amygdala whereas D1 receptors are more selectively expressed in the BLA (Abraham, Neve, & Lattal, 2014; Weiner et al., 1991) .
Taken together, these findings suggest that dopamine signaling should modulate fear suppression and reward discrimination in our safety-fear-reward cue discrimination task. We tested this hypothesis by administering a D1 dopamine receptor agonist or antagonist, systemically or infused into the BLA, before training sessions in which rats were learning to discriminate among fear, safety and reward cues.
Materials and methods

Subjects
Seventy Long Evans male rats (Harlan/Envigo) weighing 300-350 g were single housed (12 h light/dark cycle, lights on 09:00) and handled for 1 week before commencing experiments. All procedures were performed during the light cycle and approved by the Purdue Animal Care and Use Committee. Rats had ad libitum access to food and water up until the first training session, when they were restricted to 20 g of food per day for the remainder of the experiment.
Apparatus
Operant chambers were Plexiglas boxes (32 cm length × 25 cm width × 30 cm height) encased in sound-attenuating chambers (Med Associates, ST Albans, VT). 10% liquid sucrose (100 µL) was delivered through a recessed port 2 cm above the floor in the center of one wall. Port entries and exits were monitored through an infrared beam. Two lights (28 V, 100 mA) located 10.5 cm from floor on either side of the port served as the 20-s continuous light cue. A light (28 V, 100 mA) 27 cm above the floor on the wall opposite the port provided constant illumination. Auditory cues were delivered via a "tweeter" speaker (ENV-224BM) located 24 cm from the floor on the same wall as the port. Footshocks were delivered through a grid floor via a constant current aversive stimulator (ENV-414S). A side video camera located on the door of the sound-attenuating cubicle recorded the rat's behavior for offline video analyses.
DC behavioral training procedure
The three cues signifying reward, fear or safety were a 20 s continuous 3 kHz tone (70 dB), a 20 s pulsing 11 kHz tone (200 ms on, 200 ms off; 70 dB), or a 20 s continuous light (28 V, 100 mA), respectively. The stimuli were not counterbalanced for this study since our previous study did not find significant differences in conditioned freezing or reward seeking to any of these stimuli (Sangha et al., 2013) .
Rats first received 5 reward-only sessions on 5 separate days, which consisted of 25 pairings (ITI, 90-130 s) of the reward cue with a 3 s delivery of 10% sucrose solution (100 µL; pseudorandom delivery 10-20 s after cue onset) into a port. Rats then received a single habituation session consisting of 25 trials of reward cue-sucrose pairings, as well as 5 additional trials each of the fear cue presented alone and safety cue presented alone (ITI, . This procedure allows the animals to habituate and reduce their baseline freezing to the novel cues but does not contain enough presentations to produce latent inhibition (Sangha et al., 2013) . Rats then received 4 sessions of discriminative conditioning (DC) on 4 separate days, which consisted of 15 reward cue-sucrose pairings, 4 fear cue-footshock pairings (0.5 s, 0.45 mA footshock at cue offset), 15 trials of the fear cue and safety cue presented simultaneously without footshock, and 10 trials of the safety cue presented alone without footshock (total 44 trials, ITI 100-140 s). Inclusion of trials where the safety cue was presented alone was to provide the animal with additional trials with a safety cue-no shock contingency and to assess if freezing developed to the safety cue.
Reward-nonreward behavioral training procedure
Rats first received 5 reward-only sessions on 5 separate days, which consisted of the same 25 pairings of the reward cue with 3 s delivery of 10% sucrose solution as mentioned above. Rats then received a single habituation session consisting of 25 trials of reward cue-sucrose pairings, as well as 5 additional trials of a non-reward cue presented alone (ITI, . Rats then received 4 sessions of reward vs non-reward discrimination training on 4 separate days, which consisted of 15 reward cue-sucrose pairings and 15 non-reward cue presented alone without sucrose (total 30 trials, ITI 100-140 s).
Systemic injections
Systemic s.c. injections of a D1 receptor agonist (10 mg/kg SKF-38393) (Doty et al., 1998; Inoue, Izumi, Maki, Muraki, & Koyama, 2000) , antagonist (3. 33 µg/kg SCH-23390) (Sciascia, Mendoza, & Chaudhri, 2014) or saline were administered 20 min prior to each DC session. Similarly, the same dose of D1 receptor agonist or saline were administered 20 min prior to each Reward vs nonReward training session. To acclimate the animals to the injection procedure, all rats also received saline injections 20 min prior to the last reward session and habituation session.
Surgery
Rats were anesthetized with isoflurane and stereotaxically implanted bilaterally with stainless steel 27-gauge guide cannula dorsal to the BLA (AP −2.2 mm; ML ± 4.9 mm; DV −7.5 mm). During infusions, 32 gauge needles extended 1 mm beyond the guide cannulas into the BLA. Rats were allowed 7-10 days to recover in which they had ad libitum access to food and water. Stainless steel 32-gauge dummy cannulas were inserted into the guide cannulas between infusions.
BLA infusions
D1 dopamine receptor agonist SKF-38393 and antagonist SCH-23390 were each dissolved in 0.9% sodium chloride with concentrations of 1 μg/0.5 μL (Zarrindast, Rezayof, Sahraei, Haeri-Rohani, & Rassouli, 2003) and 0.25 μg/0.5 μL (Hikind & Maroun, 2008) , respectively. Twenty minutes prior to each DC session, 0.5 µL of the mixture was infused (0.25 μL/s) into the BLA bilaterally. The injectors were left in place for 2 min post-infusion to allow for drug diffusion. A separate group of animals received saline infusions instead. In order to habituate animals to the infusion procedure, all animals received sham infusions 20 min prior to the last reward session and habituation session.
Histology
Rats were deeply anesthetized with sodium pentobarbital, and then perfused with PBS followed by 10% formalin. Tissues were then postfixed in 30% sucrose formalin and sectioned at 50 µm with a cryostat. Sections were then plated on glass slides, stained with cresyl violet and examined under a light microscope to verify placements. 27 out of 48 rats had verified bilateral cannula placements in the BLA and only these subjects were included in the analyses.
Data analyses
Locomotion activity during the first and last five minutes of each session was scored offline by a custom-made MATLAB motion program. Motion was defined as any movement performed by animal that was not due to respiration. Fear behavior was assessed manually offline from videos by measuring freezing, defined as complete immobility with the exception of respiratory movements, which is an innate defensive behavior (Blanchard & Blanchard, 1969; Fendt & Fanselow, 1999) . The total time spent freezing during each 20 s cue was quantified and expressed as percentage. Measuring the total time the animal spent inside the reward port and at the entrance of the port with nose positioned at port entrance during each cue assessed reward seeking behavior and was expressed as percentage. Freezing and reward seeking were also assessed 20 s prior to each cue. Six individuals blind to drug treatment and cannula placement performed the manual behavioral scoring. Pearson's correlations of freezing and reward behavior values between scorers were greater than r = 0.80. Behavioral data were analyzed with either one-way or two-way ANOVAs with post hoc Dunnett's multiple comparisons or comparison with Bonferroni correction in GraphPad Prism.
Results
Experiment 1. Systemic administration of D1 receptor agonist or antagonist during safety-fear-reward cue discrimination
Twenty minutes prior to the start of each discrimination conditioning session (DC1-4), rats received a systemic injection of a D1 receptor agonist (10 mg/kg SKF-38393; n = 8), antagonist (3.33 µg/kg SCH-23390; n = 7) or saline (n = 12). During each DC session, rats were presented with cues signifying fear, reward, safety and the combined fear + safety cues.
3.1.1. Effects of systemic administration of D1 receptor agonist or antagonist on locomotion and pre-cue freezing and port activity
To examine possible locomotor impairment from systemic administration of the D1 receptor agonist or antagonist, we first analyzed motion activity during the first and last five minutes of each sessiontime epochs without any cue presentations. A two-way repeated measures ANOVA showed a significant main effect of treatment in DC4 (F (2, 24) = 4.36, p < .05), but not DC1-3. Post hoc comparison with Bonferroni correction showed that saline animals had more locomotor activity than antagonist animals in the last 5 min (p < .05) during DC4. We also assessed freezing and port activity behavior during 20 s epochs prior to each cue. A two-way ANOVA on pre-cue freezing percentage did not reveal any significant effect of session or treatment. A two-way ANOVA on pre-cue port activity showed a significant main effect of session (F(3, 81) = 9.79, p < .01) and main effect of treatment (F(2, 81) = 37.19, p < .01). Post hoc Dunnett's multiple comparisons to the saline condition showed that agonist animals had less pre-cue port activity than saline animals during DC1, DC3 and DC4 (p < .05). In contrast, antagonist animals had more pre-cue port activity than saline animals during DC1 and DC2 (p < .05). Taken together, these data indicate that systemic administration of a D1 receptor agonist or antagonist at these doses does not consistently affect overall locomotor activity or pre-cue freezing. However, the D1 agonist decreased baseline port activity whereas the D1 antagonist increased baseline port activity.
Systemic administration of D1 receptor agonist or antagonist impairs fear suppression in the presence of a safety cue
The percent time spent freezing for each cue was quantified for each DC session (Fig. 1) . Two-way ANOVAs on percent time spent freezing for each cue showed significant cue by treatment interactions for DC 2-4, but not DC1 (Table 1) . A main effect of cue was found for all 4 DC sessions (Table 1) . Post hoc Dunnett's multiple comparisons to the fear cue showed that saline treated animals displayed significantly more freezing to the fear cue than all other cues (p < .05 each) during DC2-4, indicating good fear discrimination. Animals with systemic injections of the D1 receptor agonist or antagonist did show more freezing to the fear cue than the reward cue and safety cues (p < .05 each) during sessions DC2-4. However, neither group showed significantly more freezing to the fear cue than the combined fear + safety cue (p > .05) during any of the DC sessions. This indicates that systemic injections of a D1 receptor agonist or antagonist impair fear suppression in the presence of the safety cue. A main effect of treatment was also found for each DC session (Table 1) . Post hoc Dunnett's multiple comparisons to the saline group showed higher levels of freezing to the fear cue in the saline group than the antagonist group during DC1-3. Saline animals showed lower levels of freezing to the reward and safety cues than the D1 receptor agonist treated group during sessions DC2-4. show good fear suppression during the safety cue. They showed more % freezing to the fear cue compared to the reward, fear + safety and safety cues during sessions DC2, DC3 and DC4 ( * p < .05). Systemic injections of a D1 receptor agonist (10 mg/kg SKF-38393; N = 8) or antagonist (3. 33 µg/kg SCH-23390; N = 7) impaired fear suppression in the presence of the safety cue. These animals only showed reduced freezing to the reward cue and safety cues during sessions DC2, DC3 and DC4 compared to the fear cue. Neither group showed reduced freezing to the fear + safety cue during any session compared to the fear cue. Data are expressed as means ± SEM.
Taken together, both the D1 receptor agonist and antagonist impaired fear suppression in the presence of a safety cue during DC2-4.
3.1.3. Systemic administration of D1 receptor agonist reduces reward seeking behavior when trained to fear and safety cues For each DC session, discriminatory reward seeking was also analyzed by quantifying the percent time spent in the port in response to each cue ( Fig. 2A) . Two-way ANOVAs on percent time spent in the port for each cue during each DC session showed a significant cue by treatment interaction for DC1-4 (Table 1) . A main effect of cue was also found for DC1-4 (Table 1) . Post hoc Dunnett's multiple comparisons to the reward cue showed that the saline group showed more port activity to the reward cues than all the other cues (p < .05 each) during all DC sessions. The D1 receptor antagonist group showed more port activity to the reward cues than all other cues during DC1 and 2 (p < .05 each), but not DC3 or 4 (p > .05). The D1 receptor agonist group did show more port activity during the reward cue than all other cues (p < .05) during DC1, but not during DC2-4 (p > .05). A main effect of treatment was also found for each DC session (Table 1) . Post hoc Dunnett's multiple comparisons to the saline group showed that saline animals had higher port activity to the reward cue than D1 receptor agonist treated animals (p < .05) during each DC session.
To investigate if systemic administration of the D1 receptor agonist impairs reward discrimination or general reward seeking behavior, a separate group of rats were trained for four sessions to discriminate between a reward-cue paired with sucrose versus a non-reward cue that was not paired with sucrose (Fig. 2B) ; there were no fear cues, safety cues or footshocks. Twenty minutes prior to each Reward/NonReward training session animals received a systemic injection of saline (n = 8) or the D1 receptor agonist (10 mg/kg SKF-38393; n = 8). A two way ANOVA on percentage of time spent in the port showed a significant main effect of cue in all DC sessions (DC1: F(1, 14) = 177.8, p < .01; DC2: F(1, 14) = 48.36, p < .01; DC3: F(1, 14) = 41.4, p < .01; DC4: F(1, 14) = 59.12, p < .01). There was also a main effect of treatment for DC1 and DC2 (DC1: F(1, 14) = 6.18, p < .05); DC2: F (1, 14) = 6.64, p < .05) but not in DC3 and DC4 (DC3: F(1, 14) = 1.03, p = .33; DC4: F(1, 14) = 2.73, p = .12). Post hoc Bonferroni's multiple comparisons test showed that saline and D1 receptor agonist animals had more port activity to the reward cue than non-reward cues in all DC sessions (p < .01). Post hoc Bonferroni's multiple comparisons test also showed that saline animals had more port activity to the nonreward cue than D1 receptor agonist animals in DC1 and DC2 (p < .05). This indicates that the systemic administration of D1 receptor agonist does not impair reward discrimination.
Experiment 1: Summary
Taken together, systemic injections of the D1 receptor agonist, SKF-38393, and antagonist, SCH-23390, both impair suppression of freezing to the fear cue when in the presence of the safety cue (DC4, Fig. 1 ). The D1 receptor antagonist did not significantly impair reward seeking during the reward cue when compared to the other cues. The D1 receptor agonist, however, did appear to significantly suppress reward seeking during all cues (Fig. 2) and during the 20 s pre-cue epochs. The impairment was limited to general reward seeking behavior because, systemic D1 receptor agonist administration did not impair reward discrimination in a Reward vs NonReward cue training paradigm. To minimize the negative influence of the non-specific effects of the drugs on behavioral expression, the same drugs were infused directly into the BLA in Experiment 2. 
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Neurobiology of Learning and Memory 147 (2018) 26-34 3.2. Experiment 2. BLA infusion of D1 receptor agonist or antagonist during safety-fear-reward cue discrimination Dopamine signaling within the BLA has been implicated in fear learning, fear extinction and reward learning. The systemic administration of D1 receptor agonist or antagonist could be producing its impairment in fear suppression and reward seeking by exerting its effects through the BLA. To localize the effect of D1 receptor activity, twenty minutes prior to the start of each DC session, 0.5 µL of D1 receptor agonist (1 μg/0.5 μL SKF-38393; n = 9), antagonist (0.25 μg/ 0.5 μL SCH-23390; n = 8) or saline (n = 10) were infused directly into the BLA bilaterally. Only animals with confirmed bilateral placements of cannula tips in the BLA were included in the analyses (27 of 48 animals; Fig. 3 ). During discrimination training, rats were presented with cues signifying fear, reward, safety and the combined fear + safety. The percent time spent freezing for each cue was calculated (Fig. 4) , as well as the percent time spent in the port in response to each cue (Fig. 5) .
Effects of BLA infusion of a D1 receptor agonist or antagonist on locomotion and pre-cue freezing and port activity
Very similar to our locomotion analyses after systemic administration of the D1 receptor agonist and antagonist, we also analyzed the motion activity in the first and last five minutes of each session during BLA infusion of the same drugs. A two-way repeated measures ANOVA (time by treatment) was performed on motion activity during the first and last five minutes of each DC session to look at the effect of drug on locomotor activity. No main effects of treatment were found. We also assessed freezing and port activity during 20 s epochs prior to each cue. A two-way repeated measures ANOVA on pre-cue freezing percentage showed a significant session by treatment interaction (F(6, 72) = 2.44, p < .05) and a significant main effect of treatment (F(2, 24) = 4.70, p < .05). Post hoc Dunnett's multiple comparisons to the saline condition showed that agonist animals had more pre-cue freezing than saline animals (p < .05) in just DC3. In contrast, a two-way ANOVA on pre-cue port activity did not reveal any significant effect of session or treatment. Overall, these data indicate there is no significant effect of the D1 receptor antagonist on locomotion during the first and last 5 mins of each session, pre-cue freezing or pre-cue port activity. The D1 receptor agonist also did not significantly affect locomotion during the first and last 5 mins of each session or pre-cue port activity. However, an effect on pre-cue freezing was detected with the D1 receptor agonist during DC3 but not any other session. Taken together there were no consistent effects of either drug on locomotion or pre-cue activity.
BLA infusion of a D1 receptor agonist or antagonist impairs fear suppression during a safety cue
Two-way repeated-measures ANOVAs on percent time spent 
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Neurobiology of Learning and Memory 147 (2018) 26-34 freezing for each cue (Fig. 4b) showed significant main effects of cue for each DC session (Table 2) . Post hoc Dunnett's multiple comparisons to the fear cue showed that the saline group froze significantly more to the fear cue in comparison to all other cues (p < .05) during DC1, 3 and 4, and to the reward and safety cues during DC2. The D1 receptor antagonist group showed more freezing to the fear cue in comparison to all other cues (p < .05) during DC2 and 4. This group also showed more freezing to the fear cue than the reward and safety cues, but not the combined fear + safety cue during DC3. For all DC sessions, the D1 receptor agonist group did show more freezing to the fear cue compared to the reward and safety cues, but not the combined fear + safety cue, with the exception of DC3, in which freezing to the fear cue was significantly higher than all other cues. A main effect of treatment was also found for DC1-4 (Table 2) . Post hoc Dunnett's multiple comparisons to the saline group showed that D1 receptor agonist treated animals had higher levels of freezing to the combined fear + safety cue during DC1-2, to the fear cue during DC2 and to the reward cue during DC3-4. The D1 receptor antagonist group, on the other hand, showed less freezing to the fear cue than saline animals during DC1. Two-way repeated-measures ANOVAs were also performed on just the fear cue versus fear + safety cue for each individual across DC2-4 to assess for consistent drug effects on suppressing fear in the presence of the safety cue across sessions (Fig. 4c) . Saline treated animals showed significant suppression of freezing to the fear + safety cue versus the fear cue during DC3 and DC4, whereas neither the agonist or antagonist treated animals showed significant suppression during any of the sessions. Taken together this indicates the global effect, across sessions, of the agonist and antagonist was impairment of fear suppression during a safety cue. This also indicates that BLA infusion of the agonist and antagonist replicated the findings with systemic treatments of the same drugs.
BLA infusion of D1 receptor agonist or antagonist does not impair discriminatory reward seeking behavior
A two-way repeated-measures ANOVA on percentage of time spent in the port (Fig. 5) showed a significant main effect of cue for DC1-4 (Table 2) . Post hoc Dunnett's multiple comparisons to the reward cue showed that the saline and antagonist groups exhibited more port activity to the reward cue in comparison to the other cues for all DC sessions. The agonist group also showed more port activity to the reward cue than the other cues during DC1 and 2. This group also showed more port activity to the reward cue than the fear + safety and safety cues, but not the fear cue, during DC3 and 4. Overall, this indicates that infusing an agonist or antagonist into the BLA does not impair discriminative reward behavior.
Discussion
In summary, we have tested the effects of a D1 receptor agonist and antagonist administered either systemically or directly into the BLA on both freezing and reward seeking behaviors during a safety-fear-reward cue discrimination task. Our data show that both the agonist and antagonist interfered with fear suppression in the presence of the safety cue, both systemically ( Fig. 1) and via intra-BLA infusion (Fig. 4) . This indicates that altering D1 receptor activity in the basolateral amygdala impairs fear suppression during a safety cue. Neither the agonist or antagonist had a consistent negative impact on discriminatory reward seeking when infused into the BLA (Fig. 5) . However, systemic administration of the D1 receptor agonist did reduce reward seeking behavior during a task that included fear and safety cues ( Fig. 2A) . We did not observe a negative impact on reward seeking during systemic administration of a D1 receptor agonist in a task that only included reward cue + sucrose and nonreward cue + no sucrose pairings (Fig. 2B) . This indicates the impairments we saw with the agonist in the safetyfear-reward cue discrimination task ( Fig. 2A) were more likely due to effects on fear and/or motivation rather than on cue discrimination.
Animals that received systemic or BLA administration of the agonist or antagonist were still able to show more freezing to the fear cue than the reward and safety cues, demonstrating some level of fear discrimination. However, these animals did not show increased freezing to the fear cue relative to the fear + safety cue, demonstrating a selective impairment in suppressing freezing to the fear cue in the presence of the safety cue. Since the amygdala typically shows a higher cue-evoked field potential to a fear cue compared to a safety cue (Rogan, Leon, Perez, & Kandel, 2005) , the impairment caused by the agonist may have been due to blocking the necessary decrease in amygdala activity during safety learning, which lead to behavioral impairments in safety but not fear behavior. Since increasing D2 receptor activity in the VTA blocks learning related increases in dopamine levels within the BLA during fear conditioning (de Oliveira et al., 2011) , it implies that BLA dopamine levels are mediated by the VTA. Blockade of dopamine activity in the nucleus accumbens impairs learning extinction of conditioned fear (Holtzman-Assif, Laurent, & Westbrook, 2010) , which would be consistent with our systemic D1 antagonist findings. However, we also saw impairment in inhibiting fear to the fear + safety cue when we limited the D1 antagonist to the BLA. It is possible that dopamine activity in both the BLA and nucleus accumbens is contributing to learning to inhibit fear responses since the impairments we saw during BLA infusions of the antagonist were not as pronounced as they were when applied systemically. Interestingly, it has been shown that synaptic plasticity in the cortical pathway onto BLA principal neurons may be regulated by the timing of D1 receptor activation (Li & Rainnie, 2014) , suggesting the impairments we see with both the agonist and antagonist, particularly when infused directly into the BLA, could be due to interference with the timing of D1 receptor signaling.
Manipulating dopamine receptor activity has been reported to affect locomotion activity (Pezze, Marshall, & Cassaday, 2016; Tran et al., 2005) . To avoid this problem, we used dosages that have been 
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Neurobiology of Learning and Memory 147 (2018) 26-34 published by other labs using the same method of administration as the current study (Doty et al., 1998; Hikind & Maroun, 2008; Inoue et al., 2000; Sciascia et al., 2014; Zarrindast et al., 2003) . In addition, examining the first and last five minutes of locomotor activity of each training session did not show impairment in locomotion activity for any treatment conditions nor did analyses of freezing levels 20 s prior to each cue. For discriminative reward behavior, it appears that D1 receptor activity in the BLA is not needed. The impairments we observed in discriminative reward seeking with the systemically administered D1 receptor agonist was not replicated in a training paradigm that utilized just a reward cue paired with sucrose and a nonreward cue not paired -38393 ; N = 9), resulted in significantly less freezing during the fear + safety, safety and reward cues when compared to the fear cue. The D1 receptor agonist group only showed reduced % time freezing to the reward, fear + safety and safety cues compared to the fear cue during DC3 ( * p < .05). The D1 receptor antagonist group showed reduced % time freezing to the reward, fear + safety and safety cues compared to the fear cue during DC2 and DC4 ( * p < .05). All data are expressed as means ± SEM. (C) For each drug treatment across DC2, DC3 and DC4, percent time freezing for each individual animal is plotted in response to the fear cue and fear + safety cue. Only the saline treated animals showed a significant reduction in freezing to the fear + safety cue when compared to the fear cue during DC3 and DC4. with sucrose; systemic administration of the D1 receptor agonist had no effect on discriminatory reward seeking. This implies that the decrease in reward seeking in the safety-fear-reward cue discrimination task was likely due to increased fear caused by the fear cue condition rather than an effect on discrimination per se.
Interestingly, under the systemic influence of the D1 receptor agonist we observed increased freezing to all cues. Although freezing was significantly lower to the reward and safety cues compared to the fear and fear + safety cues, the D1 receptor agonist did elevate the amount of freezing to each cue compared to the other drug treatments. In parallel, we observed significantly reduced reward seeking in the D1 agonist treated animals during the same sessions. Reduced reward seeking in a protocol that did not include footshocks was not as pronounced, indicating the increase in freezing and fear was causing the reduction in reward seeking in a protocol that includes both footshocks and rewards. These observations highlight the power a successfully learned safety cue can have on modulating both fear and reward behaviors.
The impairment in baseline reward seeking behavior in D1 receptor agonist animals is observable in the 20 s pre-cue port activity. In addition, these animals showed discriminative port activity similar to saline and antagonist treated animals during the first discrimination training session to the reward cue. Then, all port activity diminished over each subsequent session. Our experiment with Reward vs NonReward training confirmed that systemic administration of D1 receptor agonist does not affect reward discrimination. This impairment in baseline reward seeking is not due to D1 receptor action in the BLA because BLA infusion of the D1 receptor agonist had no effect on the discriminative reward behavior. Alternatively, the impairment could be due to receptor action in the nucleus accumbens (NAc). D1 receptor activity in the NAc is necessary for consumption behavior (Richard & Berridge, 2011) , and the reinstatement of drug seeking during stress (Tobin, Sedki, Abbas, & Shalev, 2013) . Dopamine levels in the NAc also gradually increase during different phases of operant behavior that lead to reward outcome (Collins et al., 2016) . This change in dopamine levels is influenced by the BLA and it is D1 receptor activity dependent (Stuber et al., 2011) . Activation of this pathway induces reward seeking (Stuber et al., 2011) and inactivation of BLA using a muscimol/baclofen mixture impairs approach behavior to the port (Jones et al., 2010) . In light of these findings, it is possible that increasing D1 receptor activity in the NAc via a systemically administered D1 receptor agonist during reward seeking may be reinforcing on its own and may occlude reward seeking behavioral expression.
Our current study indicates that altering dopamine D1 receptor activity in the BLA may be a potential mechanism that leads to the impairment in fear suppression to the safety signal seen with PTSD patients. Since the VTA is the primary source of dopamine for the BLA, the VTA might be providing safety information to the BLA. Alterations in dopamine release in the VTA-BLA pathway may contribute to the impairment in fear suppression to the safety signal in PTSD. Enhanced dopamine release may occlude the necessary phasic increase in dopamine release in the VTA-BLA pathway during fear learning whereas decreased dopamine release may occlude the necessary phasic decrease in dopamine levels in the VTA-BLA pathway during safety learning.
In conclusion, we show that altering D1 receptor activity in the BLA impairs fear suppression to a safety signal. Currently, it is unclear if inactivating the dopaminergic pathway from the VTA to BLA drives safety behavior. It is also unclear if increased dopamine D1 receptor activity in the NAc interferes with reward seeking. Future studies will test if activation of the VTA to BLA dopamine pathway during fear, safety and reward cue discrimination will produce the same impairment in fear/safety discrimination observed here. 
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